Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues

Summary Introduction of the proteasome inhibitor bortezomib and the immunomodulatory drugs thalidomide and lenalidomide has substantially improved outcomes for patients with multiple myeloma. As a result, these drugs have become cornerstones of current antimyeloma treatment regimens. However, after...

Full description

Saved in:
Bibliographic Details
Published in:The lancet oncology 2010-11, Vol.11 (11), p.1086-1095
Main Authors: Delforge, Michel, Prof, Bladé, Joan, Prof, Dimopoulos, Meletios A, Prof, Facon, Thierry, Prof, Kropff, Martin, MD, Ludwig, Heinz, Prof, Palumbo, Antonio, Prof, Van Damme, Philip, MD, San-Miguel, Jesús F, Prof, Sonneveld, Pieter, Prof
Format: Article
Language:English
Subjects:
Antineoplastic Agents - adverse effects
Boronic Acids - adverse effects
Bortezomib
Drug dosages
Drugs
Hematology
Hematology, Oncology and Palliative Medicine
Humans
Immunomodulation
Incidence
Multiple myeloma
Multiple Myeloma - drug therapy
Neurotoxicity
Patients
Peripheral Nervous System Diseases - chemically induced
Peripheral Nervous System Diseases - diagnosis
Peripheral Nervous System Diseases - epidemiology
Peripheral Nervous System Diseases - prevention & control
Peripheral neuropathy
proteasome inhibitors
Pyrazines - adverse effects
Quality of life
Reviews
Risk Assessment
Risk Factors
Side effects
Thalidomide
Thalidomide - adverse effects
Toxicity
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Summary Introduction of the proteasome inhibitor bortezomib and the immunomodulatory drugs thalidomide and lenalidomide has substantially improved outcomes for patients with multiple myeloma. As a result, these drugs have become cornerstones of current antimyeloma treatment regimens. However, after several years of clinical experience it has become apparent that peripheral neuropathy is the most common and potentially disabling non-haematological side-effect associated with thalidomide and bortezomib. Maximising treatment benefit while preserving quality of life therefore requires a careful balance between achieving optimum activity and minimising toxicity, including neuropathy, to further enhance efficacy. In this review, we discuss all aspects of drug-induced peripheral neuropathy in myeloma, with a particular focus on thalidomide and bortezomib.
ISSN:1470-2045
1474-5488
DOI:10.1016/S1470-2045(10)70068-1